IMS Health Economics and Outcomes Research has considerable expertise and database knowledge gained from experience in the US, European and Asia Pacific markets that can be used to help you to assess current market status and growth potential, as well as identify new opportunities. At the heart of IMS's research capabilities in this area are the IMS Disease Analyzer, and the PharMetrics Profiler series. In addition to these we have data expertise via IMS Oncology Analyzer and Acute cardiovascular databases.
Disease Analyzer is a unique longitudinal patient database sourced from primary care physicians that tracks patients and their resource use across a variety of treatment pathways in four European countries (Austria, France, Germany and the UK) combining 15.7 million individual patient records with some patients followed for 14 years.
IMS Oncology Analyzer is a diary-derived database of comprehensive patient case history information, based on advanced reporting from hospital clinicians. It provides a full therapeutic itinerary by patient from present day back to diagnosis enabling all aspects of the cancer treatment process to be analysed:
-
Full treatment history - surgery, radiotherapy, chemotherapy, supportive care
-
Patient segmentation - by indication, stage and line of therapy
-
Patient pathways and initiation of prescribing
-
Prescriber, patient & product profiling
-
Treatment practice patterns
-
Product uptake and penetration
Similar information is available for patients with Acute Cardiovascular Diseases and Stroke treated in hospitals.
PharMetrics uses the largest available data source of integrated medical and pharmaceutical claims in the USA, to provide marketers with a complete picture of patient treatment across the continuum of care. With more than 55 million unique individuals represented by more than 85 health plans, this databank started in 1995 is truly representative of the US population.